Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    12
    ...
ATC Name B/G Ingredients Dosage Form Price
N06AB10 CITOLES G Escitalopram (oxalate) - 10mg 10mg Tablet, film coated 511,940 L.L
R06AX13 CLARA G Loratadine (micronised) - 5mg/5ml 5mg/5ml Syrup 215,015 L.L
A12AA04 CALPEROS G Calcium (carbonate) - 500mg 500mg Tablet 630,262 L.L
N06AB10 CITOXAL G Escitalopram (oxalate) - 10mg 10mg Tablet, film coated 1,410,395 L.L
H01BB03 CARBETOCINA GP-PHARM G Carbetocin - 100mcg 100mcg Injectable solution 9,041,227 L.L
C09DA04 CONVERIUM PLUS G Irbesartan - 300mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 395,090 L.L
C07AB07 CARDIOSAFE 10 G Bisoprolol fumarate - 10mg 10mg Tablet, coated 610,104 L.L
G01AA10 CLINDAMYCIN G Clindamycin - 100mg 100mg Ovule 712,876 L.L
J01XB01 COLISTIMETHATE SODIQUE PANPHARMA G Colistimethate Sodium - 1.000.000IU 1.000.000IU Injectable powder for solution, Inhalation powder 6,392,659 L.L
J01XB01 COLISTIN HIKMA G Colistimethate Sodium - 1MIU 1MIU Injectable powder for solution, Inhalation powder 903,062 L.L
J01XB01 COLISTIN/NORMA G Colistimethate Sodium - 1MIU 1MIU Injectable solution 872,154 L.L
N06AB10 CITOXAL G Escitalopram (oxalate) - 15mg 15mg Tablet, film coated 2,166,786 L.L
J01XB01 COLIXIN G Colistimethate Sodium - 1,000,000IU 1,000,000IU Injectable powder for solution, Inhalation powder 20,296,042 L.L
G01AF02 CANAGYN G Clotrimazole - 100mg 100mg Tablet 229,797 L.L
J01XB01 COLISTIMETHATE G Colistimethate Sodium - 150mg 150mg Injectable powder for solution 38,239,924 L.L
M01AH01 CELECOXIB BIOGARAN G Celecoxib - 100mg 100mg Capsule 318,491 L.L
L01EJ01 CELEZON G Ruxolitinib - 5mg 5mg Tablet L.L
L01EJ01 CELEZON G Ruxolitinib - 15mg 15mg Tablet L.L
C09DA06 CANDESARTAN / HYDROCHLOROTHIAZIDE BIOGARAN G Candesartan cilexetil - 16mg, Hydrochlorothiazide - 12.5mg Tablet 327,898 L.L
G01AF02 CANAGYN G Clotrimazole - 500mg 500mg Tablet 302,365 L.L
M01AH01 CELECOXIB ARROW LAB G Celecoxib - 200mg 200mg Capsule 561,726 L.L
L01EJ01 CELEZON G Ruxolitinib - 20mg 20mg Tablet L.L
M01AH01 CELECOXIB BIOGARAN G Celecoxib - 200mg 200mg Capsule 638,325 L.L
N06AB10 CITOXAL G Escitalopram (oxalate) - 20mg 20mg Tablet, film coated 2,559,700 L.L
C09DA06 CANDESARTAN / HYDROCHLOROTHIAZIDE BIOGARAN G Candesartan cilexetil - 8mg, Hydrochlorothiazide - 12.5mg Tablet 327,898 L.L
N04BA02 CARLEVO G Levodopa - 250mg, Carbidopa - 25mg Tablet 796,067 L.L
N04BA02 CARLEVO G Levodopa - 100mg, Carbidopa - 25mg Tablet 2,431,715 L.L
N04BA03 COMBIPAR G Levodopa - 100mg, Carbidopa - 25mg, Entacapone - 200mg Tablet, film coated 1,249,926 L.L
N04BA03 COMBIPAR G Levodopa - 150mg, Carbidopa - 37.5mg, Entacapone - 200mg Tablet, film coated 1,324,682 L.L
N06AB10 CITOXAL G Escitalopram (oxalate) - 5mg 5mg Tablet, film coated 895,895 L.L
    ...
    12
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025